These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 25559329)

  • 21. Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population.
    Gellert-Kristensen H; Richardson TG; Davey Smith G; Nordestgaard BG; Tybjaerg-Hansen A; Stender S
    Hepatology; 2020 Sep; 72(3):845-856. PubMed ID: 32190914
    [TBL] [Abstract][Full Text] [Related]  

  • 22. I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease.
    Park JH; Cho B; Kwon H; Prilutsky D; Yun JM; Choi HC; Hwang KB; Lee IH; Kim JI; Kong SW
    Liver Int; 2015 Dec; 35(12):2537-46. PubMed ID: 26148225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Genetic Variant I148M in PNPLA3 Is Associated With Increased Hepatic Retinyl-Palmitate Storage in Humans.
    Kovarova M; Königsrainer I; Königsrainer A; Machicao F; Häring HU; Schleicher E; Peter A
    J Clin Endocrinol Metab; 2015 Dec; 100(12):E1568-74. PubMed ID: 26439088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-alcoholic fatty liver disease, metabolic syndrome and patatin-like phospholipase domain-containing protein3 gene variants.
    Del Ben M; Polimeni L; Brancorsini M; Di Costanzo A; D'Erasmo L; Baratta F; Loffredo L; Pastori D; Pignatelli P; Violi F; Arca M; Angelico F
    Eur J Intern Med; 2014 Jul; 25(6):566-70. PubMed ID: 24947770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduction of Caloric Intake Might Override the Prosteatotic Effects of the PNPLA3 p.I148M and TM6SF2 p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study.
    Krawczyk M; Stachowska E; Milkiewicz P; Lammert F; Milkiewicz M
    Digestion; 2016; 93(2):139-48. PubMed ID: 26745555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B.
    Chan AW; Wong GL; Chan HY; Tong JH; Yu YH; Choi PC; Chan HL; To KF; Wong VW
    J Gastroenterol Hepatol; 2017 Mar; 32(3):667-676. PubMed ID: 27547913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
    Charrez B; Qiao L; Hebbard L
    World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. I148M variant of PNPLA3 increases the susceptibility to non-alcoholic fatty liver disease caused by obesity and metabolic disorders.
    Xia MF; Ling Y; Bian H; Lin HD; Yan HM; Chang XX; Li XM; Ma H; Wang D; Zhang LS; Wang SS; Wu BJ; He WY; Zhao NQ; Gao X
    Aliment Pharmacol Ther; 2016 Mar; 43(5):631-42. PubMed ID: 26765961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The common PNPLA3 variant p.I148M is associated with liver fat contents as quantified by controlled attenuation parameter (CAP).
    Arslanow A; Stokes CS; Weber SN; Grünhage F; Lammert F; Krawczyk M
    Liver Int; 2016 Mar; 36(3):418-26. PubMed ID: 26264356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis.
    Guyot E; Sutton A; Rufat P; Laguillier C; Mansouri A; Moreau R; Ganne-Carrié N; Beaugrand M; Charnaux N; Trinchet JC; Nahon P
    J Hepatol; 2013 Feb; 58(2):312-8. PubMed ID: 23069476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The PNPLA3 rs738409 C > G polymorphism is associated with the risk of progression to cirrhosis in NAFLD patients.
    Vespasiani-Gentilucci U; Gallo P; Porcari A; Carotti S; Galati G; Piccioni L; De Vincentis A; Dell'Unto C; Vorini F; Morini S; Riva E; Picardi A
    Scand J Gastroenterol; 2016 Aug; 51(8):967-73. PubMed ID: 27150500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population.
    Wang CW; Lin HY; Shin SJ; Yu ML; Lin ZY; Dai CY; Huang JF; Chen SC; Li SS; Chuang WL
    Liver Int; 2011 Oct; 31(9):1326-31. PubMed ID: 21745282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery.
    Krawczyk M; Jiménez-Agüero R; Alustiza JM; Emparanza JI; Perugorria MJ; Bujanda L; Lammert F; Banales JM
    Surg Obes Relat Dis; 2016 Dec; 12(10):1838-1846. PubMed ID: 27576208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NAFLD in 2014: Genetics, diagnostics and therapeutic advances in NAFLD.
    Rinella ME; Sanyal AJ
    Nat Rev Gastroenterol Hepatol; 2015 Feb; 12(2):65-6. PubMed ID: 25560844
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The genetic backgrounds in nonalcoholic fatty liver disease.
    Seko Y; Yamaguchi K; Itoh Y
    Clin J Gastroenterol; 2018 Apr; 11(2):97-102. PubMed ID: 29492830
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PNPLA3 Ile148Met variant and hepatocellular carcinoma: a matter of fat.
    Valenti L
    Dig Liver Dis; 2012 Dec; 44(12):974-5. PubMed ID: 23010516
    [No Abstract]   [Full Text] [Related]  

  • 37. Association between PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma in Asian chronic hepatitis C patients: A longitudinal study.
    Yen YH; Tsai MC; Wu CK; Chang KC; Hung CH; Chiu KW; Lu SN; Wang JH; Chen CH; Kee KM; Kuo YH; Tseng PL; Lin MT; Huang CM; Lin JT; Hu TH
    J Formos Med Assoc; 2018 Sep; 117(9):833-840. PubMed ID: 29089161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial.
    Scorletti E; West AL; Bhatia L; Hoile SP; McCormick KG; Burdge GC; Lillycrop KA; Clough GF; Calder PC; Byrne CD
    J Hepatol; 2015 Dec; 63(6):1476-83. PubMed ID: 26272871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential role of oxidative DNA damage in the impact of PNPLA3 variant (rs 738409 C>G) in hepatocellular carcinoma risk.
    Limagne E; Cottet V; Cotte AK; Hamza S; Hillon P; Latruffe N; Delmas D;
    Hepatology; 2014 Sep; 60(3):1110-1. PubMed ID: 24425147
    [No Abstract]   [Full Text] [Related]  

  • 40. PNPLA3 Expression Is Related to Liver Steatosis in Morbidly Obese Women with Non-Alcoholic Fatty Liver Disease.
    Aragonès G; Auguet T; Armengol S; Berlanga A; Guiu-Jurado E; Aguilar C; Martínez S; Sabench F; Porras JA; Ruiz MD; Hernández M; Sirvent JJ; Del Castillo D; Richart C
    Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27128907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.